A novel biomarker selection method using multimodal neuroimaging data

PLoS One. 2024 Apr 4;19(4):e0289401. doi: 10.1371/journal.pone.0289401. eCollection 2024.

Abstract

Identifying biomarkers is essential to obtain the optimal therapeutic benefit while treating patients with late-life depression (LLD). We compare LLD patients with healthy controls (HC) using resting-state functional magnetic resonance and diffusion tensor imaging data to identify neuroimaging biomarkers that may be potentially associated with the underlying pathophysiology of LLD. We implement a Bayesian multimodal local false discovery rate approach for functional connectivity, borrowing strength from structural connectivity to identify disrupted functional connectivity of LLD compared to HC. In the Bayesian framework, we develop an algorithm to control the overall false discovery rate of our findings. We compare our findings with the literature and show that our approach can better detect some regions never discovered before for LLD patients. The Hub of our discovery related to various neurobehavioral disorders can be used to develop behavioral interventions to treat LLD patients who do not respond to antidepressants.

MeSH terms

  • Bayes Theorem
  • Biomarkers
  • Brain / pathology
  • Depression
  • Diffusion Tensor Imaging*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Neuroimaging*

Substances

  • Biomarkers

Grants and funding

The author(s) received no specific funding for this work.